SLC41A3 Exhibits as a Carcinoma Biomarker and Promoter in Liver Hepatocellular Carcinoma

Liver Hepatocellular Carcinoma (LIHC) is the fifth widely occurred carcinoma, which is thought to be the second primary contributor of carcinoma-associated death. There are almost 788,000 death tolls worldwide. Solute carrier family 41 member 3 (SLC41A3) is a member of solute carrier family 41, and...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Qimeng Chang, Yayun Xu, Jianfa Wang, Hui Jing, Longhua Rao, Weiguo Tang, Ziping Zhang, Xubo Wu
Formato: article
Lenguaje:EN
Publicado: Hindawi Limited 2021
Materias:
Acceso en línea:https://doaj.org/article/6a7818cd49c449fab1d2d834420a1ea2
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:6a7818cd49c449fab1d2d834420a1ea2
record_format dspace
spelling oai:doaj.org-article:6a7818cd49c449fab1d2d834420a1ea22021-11-29T00:55:26ZSLC41A3 Exhibits as a Carcinoma Biomarker and Promoter in Liver Hepatocellular Carcinoma1748-671810.1155/2021/8556888https://doaj.org/article/6a7818cd49c449fab1d2d834420a1ea22021-01-01T00:00:00Zhttp://dx.doi.org/10.1155/2021/8556888https://doaj.org/toc/1748-6718Liver Hepatocellular Carcinoma (LIHC) is the fifth widely occurred carcinoma, which is thought to be the second primary contributor of carcinoma-associated death. There are almost 788,000 death tolls worldwide. Solute carrier family 41 member 3 (SLC41A3) is a member of solute carrier family 41, and it is the key point of numerous researches. Our research attempted to explore the links between SLC41A3 and LIHC through public databases. Higher expression of SLC41A3 displayed an intimate association with higher pathological stages and poorer prognosis. GO and KEGG analysis revealed the possible regulatory pathways of SLC41A3. Additionally, we carried out cell functional experiments to determine the expression of SLC41A3 in the cell lines of LIHC, as well as the effects of its silence on cell proliferation, migration, and invasion. Our data showed that SLC41A3 was greatly increased in the cell lines of LIHC. Moreover, silencing SLC41A3 impeded LIHC cell proliferation, migration, and invasion in vitro. Collectively, our study demonstrated that highly expressed SLC41A3 was a probable indication of LIHC occurrence, and SLC41A3 could be regarded as a prospective target in the treatment of LIHC.Qimeng ChangYayun XuJianfa WangHui JingLonghua RaoWeiguo TangZiping ZhangXubo WuHindawi LimitedarticleComputer applications to medicine. Medical informaticsR858-859.7ENComputational and Mathematical Methods in Medicine, Vol 2021 (2021)
institution DOAJ
collection DOAJ
language EN
topic Computer applications to medicine. Medical informatics
R858-859.7
spellingShingle Computer applications to medicine. Medical informatics
R858-859.7
Qimeng Chang
Yayun Xu
Jianfa Wang
Hui Jing
Longhua Rao
Weiguo Tang
Ziping Zhang
Xubo Wu
SLC41A3 Exhibits as a Carcinoma Biomarker and Promoter in Liver Hepatocellular Carcinoma
description Liver Hepatocellular Carcinoma (LIHC) is the fifth widely occurred carcinoma, which is thought to be the second primary contributor of carcinoma-associated death. There are almost 788,000 death tolls worldwide. Solute carrier family 41 member 3 (SLC41A3) is a member of solute carrier family 41, and it is the key point of numerous researches. Our research attempted to explore the links between SLC41A3 and LIHC through public databases. Higher expression of SLC41A3 displayed an intimate association with higher pathological stages and poorer prognosis. GO and KEGG analysis revealed the possible regulatory pathways of SLC41A3. Additionally, we carried out cell functional experiments to determine the expression of SLC41A3 in the cell lines of LIHC, as well as the effects of its silence on cell proliferation, migration, and invasion. Our data showed that SLC41A3 was greatly increased in the cell lines of LIHC. Moreover, silencing SLC41A3 impeded LIHC cell proliferation, migration, and invasion in vitro. Collectively, our study demonstrated that highly expressed SLC41A3 was a probable indication of LIHC occurrence, and SLC41A3 could be regarded as a prospective target in the treatment of LIHC.
format article
author Qimeng Chang
Yayun Xu
Jianfa Wang
Hui Jing
Longhua Rao
Weiguo Tang
Ziping Zhang
Xubo Wu
author_facet Qimeng Chang
Yayun Xu
Jianfa Wang
Hui Jing
Longhua Rao
Weiguo Tang
Ziping Zhang
Xubo Wu
author_sort Qimeng Chang
title SLC41A3 Exhibits as a Carcinoma Biomarker and Promoter in Liver Hepatocellular Carcinoma
title_short SLC41A3 Exhibits as a Carcinoma Biomarker and Promoter in Liver Hepatocellular Carcinoma
title_full SLC41A3 Exhibits as a Carcinoma Biomarker and Promoter in Liver Hepatocellular Carcinoma
title_fullStr SLC41A3 Exhibits as a Carcinoma Biomarker and Promoter in Liver Hepatocellular Carcinoma
title_full_unstemmed SLC41A3 Exhibits as a Carcinoma Biomarker and Promoter in Liver Hepatocellular Carcinoma
title_sort slc41a3 exhibits as a carcinoma biomarker and promoter in liver hepatocellular carcinoma
publisher Hindawi Limited
publishDate 2021
url https://doaj.org/article/6a7818cd49c449fab1d2d834420a1ea2
work_keys_str_mv AT qimengchang slc41a3exhibitsasacarcinomabiomarkerandpromoterinliverhepatocellularcarcinoma
AT yayunxu slc41a3exhibitsasacarcinomabiomarkerandpromoterinliverhepatocellularcarcinoma
AT jianfawang slc41a3exhibitsasacarcinomabiomarkerandpromoterinliverhepatocellularcarcinoma
AT huijing slc41a3exhibitsasacarcinomabiomarkerandpromoterinliverhepatocellularcarcinoma
AT longhuarao slc41a3exhibitsasacarcinomabiomarkerandpromoterinliverhepatocellularcarcinoma
AT weiguotang slc41a3exhibitsasacarcinomabiomarkerandpromoterinliverhepatocellularcarcinoma
AT zipingzhang slc41a3exhibitsasacarcinomabiomarkerandpromoterinliverhepatocellularcarcinoma
AT xubowu slc41a3exhibitsasacarcinomabiomarkerandpromoterinliverhepatocellularcarcinoma
_version_ 1718407773735092224